P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models.  The independently conducted studies were funded by a grant from the National Institutes of Health (NIH). Click here to read the entire […]